Search

Your search keyword '"Vegas H"' showing total 23 results
Start Over Author "Vegas H"
23 results on '"Vegas H"'

1. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

Author

Ray-Coquard, I.L., primary, Bompas, E., additional, Cropet, C., additional, Donnat, M., additional, Bertucci, F., additional, Chaigneau, L., additional, Metzger, S., additional, Dufresne, A., additional, Guillemet, C., additional, Pacaut Vassal, C., additional, Vénat-Bouvet, L., additional, Vegas, H., additional, Piperno-Neumann, S., additional, Fabbro, M., additional, Blay, J-Y., additional, Dubray-Longeras, P., additional, Savoye, A.M., additional, Brahmi, M., additional, and Floquet, A., additional

Published
2021
Full Text
View/download PDF

2. Probing Hadronic Interactions with Measurements at Ultra-High Energies with the Pierre Auger Observatory

Author

nbsp;, D., Schmidt, A. undefined, Aab, P. undefined, Abreu, M. undefined, Aglietta, J. M. undefined, Albury, I. undefined, Allekotte, A. undefined, Almela, J. undefined, Alvarez-Muñiz, R. undefined, Alves Batista, G. A. undefined, Anastasi, L. undefined, Anchordoqui, B. undefined, Andrada, S. undefined, Andringa, C. undefined, Aramo, P. R. undefined, Araújo Ferreira, H. undefined, Asorey, P. undefined, Assis, G. undefined, Avila, A. M. undefined, Badescu, A. undefined, Bakalova, A. undefined, Balaceanu, F. undefined, Barbato, R. J. undefined, Barreira Luz, K. H. undefined, Becker, J. A. undefined, Bellido, C. undefined, Berat, M. E. undefined, Bertaina, X. undefined, Bertou, P. L. undefined, Bierman, T. undefined, Bister, J. undefined, Biteau, J. undefined, Blazek, C. undefined, Bleve, M. undefined, Boháčová, D. undefined, Boncioli, C. undefined, Bonifazi, L. undefined, Bonneau Arbeletche, N. undefined, Borodai, A. M. undefined, Botti, J. undefined, Brac, T. undefined, Bretz, F. L. undefined, Briechle, P. undefined, Buchholz, A. undefined, Bueno, S. undefined, Buitink, M. undefined, Buscemi, K. S. undefined, Caballero-Mora, L. undefined, Caccianiga, A. undefined, Cancio, F. undefined, Canfora, I. undefined, Caracas, J. M. undefined, Carceller, R. undefined, Caruso, A. undefined, Castellina, F. undefined, Catalani, G. undefined, Cataldi, L. undefined, Cazon, M. undefined, Cerda, J. A. undefined, Chinellato, K. undefined, Choi, J. undefined, Chudoba, L. undefined, Chytka, R. W. undefined, Clay, A. C. undefined, Cobos Cerutti, R. undefined, Colalillo, A. undefined, Coleman, M. R. undefined, Coluccia, R. undefined, Conceição, A. undefined, Condorelli, Consolati, G., undefined, F., Contreras, F. undefined, Convenga, C. E. undefined, Covault, S. undefined, Dasso, K. undefined, Daumiller, B. R. undefined, Dawson, J. A. undefined, Day, R. M. undefined, de Almeida, J. undefined, de Jesús, S. J. undefined, de Jong, G. undefined, De Mauro, J. R. T. undefined, de Mello Neto, I. undefined, De Mitri, J. undefined, de Oliveira, D. undefined, de Oliveira Franco, V. undefined, de Souza, E. undefined, De Vito, J. undefined, Debatin, M. undefined, del Río, O. undefined, Deligny, N. undefined, Dhital, A. undefined, Di Matteo, C. undefined, Dobrigkeit, J. C. undefined, D'Olivo, R. C. undefined, dos Anjos, M. T. undefined, Dova, J. undefined, Ebr, R. undefined, Engel, I. undefined, Epicoco, M. undefined, Erdmann, C. O. undefined, Escoba, A. undefined, Etchegoyen, H. undefined, Falcke, J. undefined, Farmer, G. undefined, Farrar, A. C. undefined, Fauth, N. undefined, Fazzi, F. undefined, Feldbusch, F. undefined, Fenu, B. undefined, Fick, J. M. undefined, Figueira, A. undefined, Filipčič, T. undefined, Fodran, M. M. undefined, Freire, T. undefined, Fujii, A. undefined, Fuster, C. undefined, Galea, C. undefined, Galelli, B. undefined, García, A. L. undefined, Garcia Vegas, H. undefined, Gemmeke, F. undefined, Gesualdi, A. undefined, Gherghel-Lascu, P. L. undefined, Ghia, U. undefined, Giaccari, M. undefined, Giammarchi, M. undefined, Giller, J. undefined, Glombitza, F. undefined, Gobbi, F. undefined, Gollan, G. undefined, Golup, M. undefined, Gómez Berisso, P. F. undefined, Gómez Vitale, J. P. undefined, Gongora, N. undefined, González, I. undefined, Goos, D. undefined, Góra, A. undefined, Gorgi, M. undefined, Gottowik, T. D. undefined, Grubb, F. undefined, Guarino, G. P. undefined, Guedes, E. undefined, Guido, S. undefined, Hahn, R. undefined, Halliday, M. R. undefined, Hampel, P. undefined, Hansen, D. undefined, Harari, V. M. undefined, Harvey, A. undefined, Haungs, T. undefined, Hebbeker, D. undefined, Heck, G. C. undefined, Hill, C. undefined, Hojvat, J. R. undefined, Hörandel, P. undefined, Horvath, M. undefined, Hrabovský, T. undefined, Huege, J. undefined, Hulsman, A. undefined, Insolia, P. G. undefined, Isar, J. A. undefined, Johnsen, J. undefined, Jurysek, A. undefined, Kääpä, K. H. undefined, Kampert, B. undefined, Keilhauer, J. undefined, Kemp, H. O. undefined, Klages, M. undefined, Kleifges, J. undefined, Kleinfeller, M. undefined, Köpke, G. undefined, Kukec Mezek, B. L. undefined, Lago, D. undefined, Lahurd, R. G. undefined, Lang, N. undefined, Langner, M. A. undefined, Leigui de Oliveira, V. undefined, Lenok, A. undefined, Letessier-Selvon, I. undefined, Lhenry-Yvon, D. undefined, Lo Presti, L. undefined, Lopes, R. undefined, López, R. undefined, Lorek, Q. undefined, Luce, A. undefined, Lucero, J. P. undefined, Lundquist, A. undefined, Machado Payeras, G. undefined, Mancarella, D. undefined, Mandat, B. C. undefined, Manning, J. undefined, Manshanden, P. undefined, Mantsc, S. undefined, Marafico, A. G. undefined, Mariazzi, I. C. undefined, Mariş, G. undefined, Marsella, D. undefined, Martello, H. undefined, Martinez, O. undefined, Martínez Bravo, M. undefined, Mastrodicasa, H. J. undefined, Mathes, J. undefined, Matthews, G. undefined, Matthiae, E. undefined, Mayotte, P. O. undefined, Mazu, G. undefined, Medina-Tanco, D. undefined, Melo, A. undefined, Menshikov, K. -D. undefined, Merenda, S. undefined, Michal, M. I. undefined, Micheletti, L. undefined, Miramonti, S. undefined, Mollerach, F. undefined, Montanet, C. undefined, Morello, M. undefined, Mostafá, A. L. undefined, Müller, M. A. undefined, Muller, K. undefined, Mulrey, R. undefined, Mussa, M. undefined, Muzio, W. M. undefined, Namasaka, L. undefined, Nellen, M. undefined, Niculescu-Oglinzanu, M. undefined, Niechciol, D. undefined, Nitz, D. undefined, Nosek, V. undefined, Novotny, L. undefined, Nožka, Nucita, A., undefined, L. A., Núñez, M. undefined, Palatka, J. undefined, Pallotta, P. undefined, Papenbreer, G. undefined, Parente, A. undefined, Parra, M. undefined, Pech, F. undefined, Pedreira, J. undefined, Pękala, R. undefined, Pelayo, J. undefined, Peña-Rodriguez, J. undefined, Perez Armand, M. undefined, Perlin, L. undefined, Perrone, S. undefined, Petrera, T. undefined, Pierog, M. undefined, Pimenta, V. undefined, Pirronello, M. undefined, Platino, B. undefined, Pont, M. undefined, Pothast, P. undefined, Privitera, M. undefined, Prouza, A. undefined, Puyleart, S. undefined, Querchfeld, J. undefined, Rautenberg, D. undefined, Ravignani, M. undefined, Reininghaus, J. undefined, Ridky, F. undefined, Riehn, M. undefined, Risse, P. undefined, Ristori, V. undefined, Rizi, W. undefined, Rodrigues de Carvalho, J. undefined, Rodriguez Rojo, M. J. undefined, Roncoroni, M. undefined, Roth, E. undefined, Roulet, A. C. undefined, Rovero, P. undefined, Ruehl, S. J. undefined, Saffi, A. undefined, Saftoiu, F. undefined, Salamida, H. undefined, Salazar, G. undefined, Salina, J. D. undefined, Sanabria Gomez, F. undefined, Sánchez, E. M. undefined, Santos, E. undefined, Santos, F. undefined, Sarazin, R. undefined, Sarmento, C. undefined, Sarmiento-Cano, R. undefined, Sato, P. undefined, Savina, C. M. undefined, Schäfer, V. undefined, Scherini, H. undefined, Schieler, M. undefined, Schimassek, M. undefined, Schimp, F. undefined, Schlüter, O. undefined, Scholten, P. undefined, Schovánek, F. G. undefined, Schröder, S. undefined, Schröder, J. undefined, Schulte, S. J. undefined, Sciutto, M. undefined, Scornavacche, R. C. undefined, Shellard, G. undefined, Sigl, G. undefined, Silli, O. undefined, Sima, R. undefined, Šmída, P. undefined, Sommers, J. F. undefined, Soriano, J. undefined, Souchard, R. undefined, Squartini, M. undefined, Stadelmaier, D. undefined, Stanca, S. undefined, Stanič, J. undefined, Stasielak, P. undefined, Stassi, A. undefined, Streich, M. undefined, Suárez-Durán, T. undefined, Sudholz, T. undefined, Suomijärvi, A. D. undefined, Supanitsky, J. undefined, Šupík, Z. undefined, Szadkowski, A. undefined, Taboada, A. undefined, Tapia, C. undefined, Timmermans, O. undefined, Tkachenko, P. undefined, Tobiska, C. J. undefined, Todero Peixoto, B. undefined, Tomé, A. undefined, Travaini, P. undefined, Travnicek, C. undefined, Trimarelli, M. undefined, Trini, M. undefined, Tueros, R. undefined, Ulrich, M. undefined, Unger, L. undefined, Vaclavek, M. undefined, Vacula, J. F. undefined, Valdés Galicia, L. undefined, Valore, E. undefined, Varela, V. undefined, Varma K. C., A. undefined, Vásquez-Ramírez, D. undefined, Veberič, C. undefined, Ventura, I. D. undefined, Vergara Quispe, V. undefined, Verzi, J. undefined, Vicha, J. undefined, Vink, S. undefined, Vorobiov, H. undefined, Wahlberg, A. A. undefined, Wat, M. undefined, Weber, A. undefined, Weindl, L. undefined, Wiencke, H. undefined, Wilczyński, T. undefined, Winchen, M. undefined, Wirtz, D. undefined, Wittkowski, B. undefined, Wundheiler, A. undefined, Yushkov, O. undefined, Zapparrata, E. undefined, Zas, D. undefined, Zavrtanik, M. undefined, Zavrtanik, L. undefined, Zehrer, A. undefined, and Zepeda

Published
2020

3. The Radio Detection of Inclined Showers at the Pierre Auger Observatory

Author

S. de Jong, A. &nbsp, Aab, P. undefined, Abreu, M. undefined, Aglietta, J. M. undefined, Albury, I. undefined, Allekotte, A. undefined, Almela, J. undefined, Alvarez-Muñiz, R. undefined, Alves Batista, G. A. undefined, Anastasi, L. undefined, Anchordoqui, B. undefined, Andrada, S. undefined, Andringa, C. undefined, Aramo, P. R. undefined, Araújo Ferreira, H. undefined, Asorey, P. undefined, Assis, G. undefined, Avila, A. M. undefined, Badescu, A. undefined, Bakalova, A. undefined, Balaceanu, F. undefined, Barbato, R. J. undefined, Barreira Luz, K. H. undefined, Becker, J. A. undefined, Bellido, C. undefined, Berat, M. E. undefined, Bertaina, X. undefined, Bertou, P. L. undefined, Bierman, T. undefined, Bister, J. undefined, Biteau, J. undefined, Blazek, C. undefined, Bleve, M. undefined, Boháčová, D. undefined, Boncioli, C. undefined, Bonifazi, L. undefined, Bonneau Arbeletche, N. undefined, Borodai, A. M. undefined, Botti, J. undefined, Brac, T. undefined, Bretz, F. L. undefined, Briechle, P. undefined, Buchholz, A. undefined, Bueno, S. undefined, Buitink, M. undefined, Buscemi, K. S. undefined, Caballero-Mora, L. undefined, Caccianiga, A. undefined, Cancio, F. undefined, Canfora, I. undefined, Caracas, J. M. undefined, Carceller, R. undefined, Caruso, A. undefined, Castellina, F. undefined, Catalani, G. undefined, Cataldi, L. undefined, Cazon, M. undefined, Cerda, J. A. undefined, Chinellato, K. undefined, Choi, J. undefined, Chudoba, L. undefined, Chytka, R. W. undefined, Clay, A. C. undefined, Cobos Cerutti, R. undefined, Colalillo, A. undefined, Coleman, M. R. undefined, Coluccia, R. undefined, Conceição, A. undefined, Condorelli, Consolati, G., undefined, F., Contreras, F. undefined, Convenga, C. E. undefined, Covault, S. undefined, Dasso, K. undefined, Daumiller, B. R. undefined, Dawson, J. A. undefined, Day, R. M. undefined, de Almeida, J. undefined, de Jesús, G. undefined, De Mauro, J. R. T. undefined, de Mello Neto, I. undefined, De Mitri, J. undefined, de Oliveira, D. undefined, de Oliveira Franco, V. undefined, de Souza, E. undefined, De Vito, J. undefined, Debatin, M. undefined, del Río, O. undefined, Deligny, N. undefined, Dhital, A. undefined, Di Matteo, C. undefined, Dobrigkeit, J. C. undefined, D'Olivo, R. C. undefined, dos Anjos, M. T. undefined, Dova, J. undefined, Ebr, R. undefined, Engel, I. undefined, Epicoco, M. undefined, Erdmann, C. O. undefined, Escoba, A. undefined, Etchegoyen, H. undefined, Falcke, J. undefined, Farmer, G. undefined, Farrar, A. C. undefined, Fauth, N. undefined, Fazzi, F. undefined, Feldbusch, F. undefined, Fenu, B. undefined, Fick, J. M. undefined, Figueira, A. undefined, Filipčič, T. undefined, Fodran, M. M. undefined, Freire, T. undefined, Fujii, A. undefined, Fuster, C. undefined, Galea, C. undefined, Galelli, B. undefined, García, A. L. undefined, Garcia Vegas, H. undefined, Gemmeke, F. undefined, Gesualdi, A. undefined, Gherghel-Lascu, P. L. undefined, Ghia, U. undefined, Giaccari, M. undefined, Giammarchi, M. undefined, Giller, J. undefined, Glombitza, F. undefined, Gobbi, F. undefined, Gollan, G. undefined, Golup, M. undefined, Gómez Berisso, P. F. undefined, Gómez Vitale, J. P. undefined, Gongora, N. undefined, González, I. undefined, Goos, D. undefined, Góra, A. undefined, Gorgi, M. undefined, Gottowik, T. D. undefined, Grubb, F. undefined, Guarino, G. P. undefined, Guedes, E. undefined, Guido, S. undefined, Hahn, R. undefined, Halliday, M. R. undefined, Hampel, P. undefined, Hansen, D. undefined, Harari, V. M. undefined, Harvey, A. undefined, Haungs, T. undefined, Hebbeker, D. undefined, Heck, G. C. undefined, Hill, C. undefined, Hojvat, J. R. undefined, Hörandel, P. undefined, Horvath, M. undefined, Hrabovský, T. undefined, Huege, J. undefined, Hulsman, A. undefined, Insolia, P. G. undefined, Isar, J. A. undefined, Johnsen, J. undefined, Jurysek, A. undefined, Kääpä, K. H. undefined, Kampert, B. undefined, Keilhauer, J. undefined, Kemp, H. O. undefined, Klages, M. undefined, Kleifges, J. undefined, Kleinfeller, M. undefined, Köpke, G. undefined, Kukec Mezek, B. L. undefined, Lago, D. undefined, Lahurd, R. G. undefined, Lang, N. undefined, Langner, M. A. undefined, Leigui de Oliveira, V. undefined, Lenok, A. undefined, Letessier-Selvon, I. undefined, Lhenry-Yvon, D. undefined, Lo Presti, L. undefined, Lopes, R. undefined, López, R. undefined, Lorek, Q. undefined, Luce, A. undefined, Lucero, J. P. undefined, Lundquist, A. undefined, Machado Payeras, G. undefined, Mancarella, D. undefined, Mandat, B. C. undefined, Manning, J. undefined, Manshanden, P. undefined, Mantsc, S. undefined, Marafico, A. G. undefined, Mariazzi, I. C. undefined, Mariş, G. undefined, Marsella, D. undefined, Martello, H. undefined, Martinez, O. undefined, Martínez Bravo, M. undefined, Mastrodicasa, H. J. undefined, Mathes, J. undefined, Matthews, G. undefined, Matthiae, E. undefined, Mayotte, P. O. undefined, Mazu, G. undefined, Medina-Tanco, D. undefined, Melo, A. undefined, Menshikov, K. -D. undefined, Merenda, S. undefined, Michal, M. I. undefined, Micheletti, L. undefined, Miramonti, S. undefined, Mollerach, F. undefined, Montanet, C. undefined, Morello, M. undefined, Mostafá, A. L. undefined, Müller, M. A. undefined, Muller, K. undefined, Mulrey, R. undefined, Mussa, M. undefined, Muzio, W. M. undefined, Namasaka, L. undefined, Nellen, M. undefined, Niculescu-Oglinzanu, M. undefined, Niechciol, D. undefined, Nitz, D. undefined, Nosek, V. undefined, Novotny, L. undefined, Nožka, Nucita, A., undefined, L. A., Núñez, M. undefined, Palatka, J. undefined, Pallotta, P. undefined, Papenbreer, G. undefined, Parente, A. undefined, Parra, M. undefined, Pech, F. undefined, Pedreira, J. undefined, Pękala, R. undefined, Pelayo, J. undefined, Peña-Rodriguez, J. undefined, Perez Armand, M. undefined, Perlin, L. undefined, Perrone, S. undefined, Petrera, T. undefined, Pierog, M. undefined, Pimenta, V. undefined, Pirronello, M. undefined, Platino, B. undefined, Pont, M. undefined, Pothast, P. undefined, Privitera, M. undefined, Prouza, A. undefined, Puyleart, S. undefined, Querchfeld, J. undefined, Rautenberg, D. undefined, Ravignani, M. undefined, Reininghaus, J. undefined, Ridky, F. undefined, Riehn, M. undefined, Risse, P. undefined, Ristori, V. undefined, Rizi, W. undefined, Rodrigues de Carvalho, J. undefined, Rodriguez Rojo, M. J. undefined, Roncoroni, M. undefined, Roth, E. undefined, Roulet, A. C. undefined, Rovero, P. undefined, Ruehl, S. J. undefined, Saffi, A. undefined, Saftoiu, F. undefined, Salamida, H. undefined, Salazar, G. undefined, Salina, J. D. undefined, Sanabria Gomez, F. undefined, Sánchez, E. M. undefined, Santos, E. undefined, Santos, F. undefined, Sarazin, R. undefined, Sarmento, C. undefined, Sarmiento-Cano, R. undefined, Sato, P. undefined, Savina, C. M. undefined, Schäfer, V. undefined, Scherini, H. undefined, Schieler, M. undefined, Schimassek, M. undefined, Schimp, F. undefined, Schlüter, D. undefined, Schmidt, O. undefined, Scholten, P. undefined, Schovánek, F. G. undefined, Schröder, S. undefined, Schröder, J. undefined, Schulte, S. J. undefined, Sciutto, M. undefined, Scornavacche, R. C. undefined, Shellard, G. undefined, Sigl, G. undefined, Silli, O. undefined, Sima, R. undefined, Šmída, P. undefined, Sommers, J. F. undefined, Soriano, J. undefined, Souchard, R. undefined, Squartini, M. undefined, Stadelmaier, D. undefined, Stanca, S. undefined, Stanič, J. undefined, Stasielak, P. undefined, Stassi, A. undefined, Streich, M. undefined, Suárez-Durán, T. undefined, Sudholz, T. undefined, Suomijärvi, A. D. undefined, Supanitsky, J. undefined, Šupík, Z. undefined, Szadkowski, A. undefined, Taboada, A. undefined, Tapia, C. undefined, Timmermans, O. undefined, Tkachenko, P. undefined, Tobiska, C. J. undefined, Todero Peixoto, B. undefined, Tomé, A. undefined, Travaini, P. undefined, Travnicek, C. undefined, Trimarelli, M. undefined, Trini, M. undefined, Tueros, R. undefined, Ulrich, M. undefined, Unger, L. undefined, Vaclavek, M. undefined, Vacula, J. F. undefined, Valdés Galicia, L. undefined, Valore, E. undefined, Varela, V. undefined, Varma K. C., A. undefined, Vásquez-Ramírez, D. undefined, Veberič, C. undefined, Ventura, I. D. undefined, Vergara Quispe, V. undefined, Verzi, J. undefined, Vicha, J. undefined, Vink, S. undefined, Vorobiov, H. undefined, Wahlberg, A. A. undefined, Wat, M. undefined, Weber, A. undefined, Weindl, L. undefined, Wiencke, H. undefined, Wilczyński, T. undefined, Winchen, M. undefined, Wirtz, D. undefined, Wittkowski, B. undefined, Wundheiler, A. undefined, Yushkov, O. undefined, Zapparrata, E. undefined, Zas, D. undefined, Zavrtanik, M. undefined, Zavrtanik, L. undefined, Zehrer, A. undefined, and Zepeda

Published
2020

4. Multi-Messenger Studies with the Pierre Auger Observatory

Author

nbsp;, L., Zehrer, A. undefined, Aab, P. undefined, Abreu, M. undefined, Aglietta, J. M. undefined, Albury, I. undefined, Allekotte, A. undefined, Almela, J. undefined, Alvarez-Muniz, R. undefined, Alves Batista, G. A. undefined, Anastasi, L. undefined, Anchordoqui, B. undefined, Andrada, S. undefined, Andringa, C. undefined, Aramo, P. R. undefined, Araújo Ferreira, H. undefined, Asorey, P. undefined, Assis, G. undefined, Avila, A. M. undefined, Badescu, A. undefined, Bakalova, A. undefined, Balaceanu, F. undefined, Barbato, R. J. undefined, Barreira Luz, K. H. undefined, Becker, J. A. undefined, Bellido, C. undefined, Berat, M. E. undefined, Bertaina, X. undefined, Bertou, P. L. undefined, Bierman, T. undefined, Bister, J. undefined, Biteau, J. undefined, Blazek, C. undefined, Bleve, M. undefined, Bohácová, D. undefined, Boncioli, C. undefined, Bonifazi, L. undefined, Bonneau Arbeletche, N. undefined, Borodai, A. M. undefined, Botti, J. undefined, Brac, T. undefined, Bretz, F. L. undefined, Briechle, P. undefined, Buchholz, A. undefined, Bueno, S. undefined, Buitink, M. undefined, Buscemi, K. S. undefined, Caballero-Mora, L. undefined, Caccianiga, A. undefined, Cancio, F. undefined, Canfora, I. undefined, Caracas, J. M. undefined, Carceller, R. undefined, Caruso, A. undefined, Castellina, F. undefined, Catalani, G. undefined, Cataldi, L. undefined, Cazon, M. undefined, Cerda, J. A. undefined, Chinellato, K. undefined, Choi, J. undefined, Chudoba, L. undefined, Chytka, R. W. undefined, Clay, A. C. undefined, Cobos Cerutti, R. undefined, Colalillo, A. undefined, Coleman, M. R. undefined, Coluccia, R. undefined, Conceicao, A. undefined, Condorelli, Consolati, G., undefined, F., Contreras, F. undefined, Convenga, C. E. undefined, Covault, S. undefined, Dasso, K. undefined, Daumiller, B. R. undefined, Dawson, J. A. undefined, Day, R. M. undefined, de Almeida, J. undefined, de Jesús, S. J. undefined, de Jong, G. undefined, De Mauro, J. R. T. undefined, de Mello Neto, I. undefined, De Mitri, J. undefined, de Oliveira, D. undefined, de Oliveira Franco, V. undefined, de Souza, E. undefined, De Vito, J. undefined, Debatin, M. undefined, del Río, O. undefined, Deligny, N. undefined, Dhital, A. undefined, Di Matteo, C. undefined, Dobrigkeit, J. C. undefined, D'Olivo, R. C. undefined, dos Anjos, M. T. undefined, Dova, J. undefined, Ebr, R. undefined, Engel, I. undefined, Epicoco, M. undefined, Erdmann, C. O. undefined, Escoba, A. undefined, Etchegoyen, H. undefined, Falcke, J. undefined, Farmer, G. undefined, Farrar, A. C. undefined, Fauth, N. undefined, Fazzi, F. undefined, Feldbusch, F. undefined, Fenu, B. undefined, Fick, J. M. undefined, Figueira, A. undefined, Filipcic, T. undefined, Fodran, M. M. undefined, Freire, T. undefined, Fujii, A. undefined, Fuster, C. undefined, Galea, C. undefined, Galelli, B. undefined, García, A. L. undefined, Garcia Vegas, H. undefined, Gemmeke, F. undefined, Gesualdi, A. undefined, Gherghel-Lascu, P. L. undefined, Ghia, U. undefined, Giaccari, M. undefined, Giammarchi, M. undefined, Giller, J. undefined, Glombitza, F. undefined, Gobbi, F. undefined, Gollan, G. undefined, Golup, M. undefined, Gómez Berisso, P. F. undefined, Gómez Vitale, J. P. undefined, Gongora, N. undefined, González, I. undefined, Goos, D. undefined, Góra, A. undefined, Gorgi, M. undefined, Gottowik, T. D. undefined, Grubb, F. undefined, Guarino, G. P. undefined, Guedes, E. undefined, Guido, S. undefined, Hahn, R. undefined, Halliday, M. R. undefined, Hampel, P. undefined, Hansen, D. undefined, Harari, V. M. undefined, Harvey, A. undefined, Haungs, T. undefined, Hebbeker, D. undefined, Heck, G. C. undefined, Hill, C. undefined, Hojvat, J. R. undefined, Horandel, P. undefined, Horvath, M. undefined, Hrabovsky, T. undefined, Huege, J. undefined, Hulsman, A. undefined, Insolia, P. G. undefined, Isar, J. A. undefined, Johnsen, J. undefined, Jurysek, A. undefined, Kaapa, K. H. undefined, Kampert, B. undefined, Keilhauer, J. undefined, Kemp, H. O. undefined, Klages, M. undefined, Kleifges, J. undefined, Kleinfeller, M. undefined, Köpke, G. undefined, Kukec Mezek, B. L. undefined, Lago, D. undefined, Lahurd, R. G. undefined, Lang, N. undefined, Langner, M. A. undefined, Leigui de Oliveira, V. undefined, Lenok, A. undefined, Letessier-Selvon, I. undefined, Lhenry-Yvon, D. undefined, Lo Presti, L. undefined, Lopes, R. undefined, López, R. undefined, Lorek, Q. undefined, Luce, A. undefined, Lucero, J. P. undefined, Lundquist, A. undefined, Machado Payeras, G. undefined, Mancarella, D. undefined, Mandat, B. C. undefined, Manning, J. undefined, Manshanden, P. undefined, Mantsc, S. undefined, Marafico, A. G. undefined, Mariazzi, I. C. undefined, Mariş, G. undefined, Marsella, D. undefined, Martello, H. undefined, Martinez, O. undefined, Martínez Bravo, M. undefined, Mastrodicasa, H. J. undefined, Mathes, J. undefined, Matthews, G. undefined, Matthiae, E. undefined, Mayotte, P. O. undefined, Mazu, G. undefined, Medina-Tanco, D. undefined, Melo, A. undefined, Menshikov, K. -D. undefined, Merenda, S. undefined, Michal, M. I. undefined, Micheletti, L. undefined, Miramonti, S. undefined, Mollerach, F. undefined, Montanet, C. undefined, Morello, M. undefined, Mostafá, A. L. undefined, Muller, M. A. undefined, Muller, K. undefined, Mulrey, R. undefined, Mussa, M. undefined, Muzio, W. M. undefined, Namasaka, L. undefined, Nellen, M. undefined, Niculescu-Oglinzanu, M. undefined, Niechciol, D. undefined, Nitz, D. undefined, Nosek, V. undefined, Novotny, L. undefined, Nožka, Nucita, A., undefined, L. A., Nunez, M. undefined, Palatka, J. undefined, Pallotta, P. undefined, Papenbreer, G. undefined, Parente, A. undefined, Parra, M. undefined, Pech, F. undefined, Pedreira, J. undefined, Pękala, R. undefined, Pelayo, J. undefined, Pena-Rodriguez, J. undefined, Perez Armand, M. undefined, Perlin, L. undefined, Perrone, S. undefined, Petrera, T. undefined, Pierog, M. undefined, Pimenta, V. undefined, Pirronello, M. undefined, Platino, B. undefined, Pont, M. undefined, Pothast, P. undefined, Privitera, M. undefined, Prouza, A. undefined, Puyleart, S. undefined, Querchfeld, J. undefined, Rautenberg, D. undefined, Ravignani, M. undefined, Reininghaus, J. undefined, Ridky, F. undefined, Riehn, M. undefined, Risse, P. undefined, Ristori, V. undefined, Rizi, W. undefined, Rodrigues de Carvalho, J. undefined, Rodriguez Rojo, M. J. undefined, Roncoroni, M. undefined, Roth, E. undefined, Roulet, A. C. undefined, Rovero, P. undefined, Ruehl, S. J. undefined, Saffi, A. undefined, Saftoiu, F. undefined, Salamida, H. undefined, Salazar, G. undefined, Salina, J. D. undefined, Sanabria Gomez, F. undefined, Sánchez, E. M. undefined, Santos, E. undefined, Santos, F. undefined, Sarazin, R. undefined, Sarmento, C. undefined, Sarmiento-Cano, R. undefined, Sato, P. undefined, Savina, C. M. undefined, Schafer, V. undefined, Scherini, H. undefined, Schieler, M. undefined, Schimassek, M. undefined, Schimp, F. undefined, Schluter, D. undefined, Schmidt, O. undefined, Scholten, P. undefined, Schovánek, F. G. undefined, Schroder, S. undefined, Schroder, J. undefined, Schulte, S. J. undefined, Sciutto, M. undefined, Scornavacche, R. C. undefined, Shellard, G. undefined, Sigl, G. undefined, Silli, O. undefined, Sima, R. undefined, Smída, P. undefined, Sommers, J. F. undefined, Soriano, J. undefined, Souchard, R. undefined, Squartini, M. undefined, Stadelmaier, D. undefined, Stanca, S. undefined, Stanic, J. undefined, Stasielak, P. undefined, Stassi, A. undefined, Streich, M. undefined, Suárez-Durán, T. undefined, Sudholz, T. undefined, Suomijärvi, A. D. undefined, Supanitsky, J. undefined, Supík, Z. undefined, Szadkowski, A. undefined, Taboada, A. undefined, Tapia, C. undefined, Timmermans, O. undefined, Tkachenko, P. undefined, Tobiska, C. J. undefined, Todero Peixoto, B. undefined, Tomé, A. undefined, Travaini, P. undefined, Travnicek, C. undefined, Trimarelli, M. undefined, Trini, M. undefined, Tueros, R. undefined, Ulrich, M. undefined, Unger, L. undefined, Vaclavek, M. undefined, Vacula, J. F. undefined, Valdés Galicia, L. undefined, Valore, E. undefined, Varela, V. undefined, Varma K. C., A. undefined, Vásquez-Ramírez, D. undefined, Veberic, C. undefined, Ventura, I. D. undefined, Vergara Quispe, V. undefined, Verzi, J. undefined, Vicha, J. undefined, Vink, S. undefined, Vorobiov, H. undefined, Wahlberg, A. A. undefined, Wat, M. undefined, Weber, A. undefined, Weindl, L. undefined, Wiencke, H. undefined, Wilczynski, T. undefined, Winchen, M. undefined, Wirtz, D. undefined, Wittkowski, B. undefined, Wundheiler, A. undefined, Yushkov, O. undefined, Zapparrata, E. undefined, Zas, D. undefined, Zavrtanik, M. undefined, Zavrtanik, A. undefined, and Zepeda

Published
2020

5. Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Author

Duffaud, F., primary, Blay, J.-Y., additional, Italiano, A., additional, Bompas, E., additional, Rios, M., additional, Penel, N., additional, Mir, O., additional, Piperno-Neumann, S., additional, Chevreau, C.M., additional, Delcambre, C., additional, Bertucci, F., additional, Boudou Rouquette, P., additional, Vegas, H., additional, Perrin, C., additional, Thyss, A., additional, Schiffler, C., additional, Monard, L., additional, Bouvier, C., additional, Vidal, V., additional, and Chabaud, S., additional

Published
2019
Full Text
View/download PDF

6. Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group

Author

de la Motte Rouge, T., primary, Derquin, F., additional, Floquet, A., additional, Edeline, J., additional, Lotz, J.-P., additional, Alexandre, J., additional, Pautier, P., additional, Ferron, G., additional, Boissier, E., additional, Lefeuvre-Plesse, C., additional, Vegas, H., additional, Patsouris, A., additional, Kalbacher, E., additional, Berton-Rigaud, D., additional, Hardy Bessard, A.-C., additional, Lavoué, V., additional, and Ray-Coquard, I.L., additional

Published
2018
Full Text
View/download PDF

7. LBA88 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Author

Duffaud, F., Blay, J.-Y., Italiano, A., Bompas, E., Rios, M., Penel, N., Mir, O., Piperno-Neumann, S., Chevreau, C.M., Delcambre, C., Bertucci, F., Boudou Rouquette, P., Vegas, H., Perrin, C., Thyss, A., Schiffler, C., Monard, L., Bouvier, C., Vidal, V., and Chabaud, S.

Published
2019
Full Text
View/download PDF

8. 938PD - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group

Author

de la Motte Rouge, T., Derquin, F., Floquet, A., Edeline, J., Lotz, J.-P., Alexandre, J., Pautier, P., Ferron, G., Boissier, E., Lefeuvre-Plesse, C., Vegas, H., Patsouris, A., Kalbacher, E., Berton-Rigaud, D., Hardy Bessard, A.-C., Lavoué, V., and Ray-Coquard, I.L.

Published
2018
Full Text
View/download PDF

9. Ranking de listas enlazadas en procesadores multicore

Author

Vegas, H., Prieto, Manuel, Garcia, C., Gautier, Thierry, Museu Nacl Hist Nat, Université de Lisbonne, PrograMming and scheduling design fOr Applications in Interactive Simulation (MOAIS), Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire d'Informatique de Grenoble (LIG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire d'Informatique de Grenoble (LIG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), and Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[INFO.INFO-DC]Computer Science [cs]/Distributed, Parallel, and Cluster Computing [cs.DC]
Abstract

National audience; En este estudio hemos revisado la implementaci 'on de algoritmos paralelos para el ranking de listas enlazadas en procesadores multicore. Este tipo de algoritmos exhibe patrones de acceso a memoria fuertemente irregulares que no se benefician de los mecanismos agresivos que integran las arquitecturas actuales para ocultar los costosos accesos a memoria (caches, mecanismos de preb'usqueda, ...). Debido a esta caracter'ıstica intr'ınseca, el rendimiento de cualquier algoritmo para el ranking de listas esta limitado por los accesos a memoria no consecutivos. En los algoritmos paralelos los problemas de rendimiento se agravan ya que los patrones de acceso irregular suelen provocar mayor contenci'on por recursos compartidos y por lo tanto, continua siendo un importante desaf'ıo dise˜nar algoritmos eficientes para esta aplicaci 'on. Tras explorar distintas alternativas, nos hemos centrado en el algoritmo de Helman y J'aj'a. Como plataforma experimental hemos seleccionado un servidor de memoria compartida con dos procesadores Intel Westmere de seis cores. Se han analizado dos implementaciones, una de ellas siguiendo el modelo de ejecuci'on convencional fork-join soportado por el est'andar OpenMP, y otra que utiliza la librer'ıa TBB (Threading Building Blocks) de Intel, con la que es posible repartir trabajo utilizando work stealing. Como principal aportaci'on mostramos como es posible mejorar la implementaci'on est'andar de Helman y J'aj'a reduciendo el n'umero de accesos a memoria no consecutivos. Las mejoras son notables con ambos modelos, aunque son especialmente significativas para la versi'on basada en Intel TBB, cuya implementaci'on est'andar no consigue aceleraciones respecto al algoritmo secuencial. Palabras clave-- List Ranking, Helman y J'aj'a, Algoritmos irregulares, OpenMP, Intel TBB, Workstealing.

Published
2011

10. Resultados del estudio geológico a escala 1/25000 del término municipal de Madrid

Author

Calvo Sorando, J. P., Goy, José Luis, Pérez-González, Alfredo, San José, M. A., Vegas, H., Zazo, Caridad, Hoyos Gómez, Manuel, Garrido Megías, A., Brell, José Manuel, Rincón, R., Ordóñez, Salvador, García del Cura, M. Ángeles, Doval, M., Rodas, Magdalena, Gallego, E., Morales, Jorge, López Martínez, Nieves, Alberdi, María Teresa, Sesé, Carmen, Soto, Enrique, Soria, Dolores, Herráez, Esther, Cerdeño, Esperanza, Álvarez Ramis, Concepción, Fernández Marrón, M. T., Querol, N., and Gallardo, J.

Subjects
Madrid, Cuaternario, Geologia, Terciario
Abstract

RESUMEN: Se exponen de forma abreviada los rasgos en cuanto a metodología y conclusiones del Estudio geológico a escala 1/25000 realizado en el Municipio de Madrid en los años 1982/83. Las diferentes unidades expresadas en la cartografía se describen en función de las pautas mayores observables en los materiales que forman cada una de ellas. analizándose sus relaciones estratigráficas. El Proyecto «Estudio Geológico a escala 1/25000 del Término Municipal de Madrid ha sido llevado a cabo a lo largo de los años 1982-83 'como resultado de la colaboración científica entre diversos organismos de la Administración (Facultad de CC. Geológicas-Universidad Complutense, Instituto Geológico y Minero, Ayuntamiento de Madrid, Instituto de Geología de Madrid-CSIC. y otros). Constituye una de las áreas de actuación definidas dentro del "Convenio de Colaboración Técnica y Cultural para el conocimiento de las Características del Suelo y Subsuelo de Madrid", propiciado y patrocinado por el Excmo. Ayuntamiento. La financiación del proyecto específico de Geología ha sido realizada íntegramente por el IGME, organismo encargado además de su supervisión. El desarrollo del Proyecto tiene un marcado carácter interdisciplinar, fruto del trasvase de información entre los distintos grupos que abarca el Convenio general (aparte de los ya referidos, el SGOP, COPLACO, Laboratorio “José Luis Escario”… ), siendo precisamente uno de los objetivos del trabajo el servir de apoyo a las restantes áreas de investigación. Los estudios geológicos realizados se plasman en un total de siete mapas a escala 1/25000 elaborados según la normativa Magna de cartografía geológica, mapas que toman como referencia, aunque en algunos casos no las completan y en otros adosan porciones de hojas adyacentes, las hojas 1/25000 de Madrid. Alcorcón. El Pardo. San Fernando de Henares. Pozuelo de Alarcón. Alcobendas y Castillo de Viñuelas.

Published
1988

12. Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.

Author

Aubert M, Mathiot L, Vegas H, Ouldamer L, Linassier C, Augereau P, Bocquet F, Frenel JS, and Cancel M

Subjects
Humans, Female, Middle Aged, Retrospective Studies, Aged, Adult, Aged, 80 and over, Quality of Life, Antineoplastic Agents, Hormonal therapeutic use, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial pathology, Carcinoma, Ovarian Epithelial mortality, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Ovarian Neoplasms mortality
Abstract

Background: In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When platinum resistant, subsequent lines of chemotherapy are of limited effect and often poorly tolerated, leading to quality of life deterioration. Various studies suggest a hormonal role in ovarian carcinogenesis, with a rationale for endocrine therapy in these cancers., Patients and Methods: This multicenter, retrospective study assessed the use of endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020., Results: Eighty-one patients with ovarian cancers were included. The median duration of platinum sensitivity was 29 months. We observed a 35% disease control rate with endocrine therapy, and 10% reported symptom improvement. For 19 patients (23.5%), the disease was stabilized for more than 6 months. Median overall survival from diagnosis was 62.6 months. Regarding endocrine therapy predictive factors of response, in a multivariate analysis, 3 factors were statistically significant in favoring progression-free survival: platinum sensitivity (P = .021), an R0 surgical resection (P = .020), and the indication for hormone therapy being maintenance therapy (P = .002)., Conclusion: This study shows real-life data on endocrine therapy in ovarian cancer. As it is a low-cost treatment with many advantages such as its oral administration and its safety, it may be an option to consider. A perspective lies in the search for cofactors to aim as future therapeutic targets to improve the effectiveness of hormone treatment by means of combination therapy., (© The Author(s) 2024. Published by Oxford University Press.)

Published
2024
Full Text
View/download PDF

13. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

Author

Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, and Delaloge S

Subjects
Humans, Female, Adolescent, Adult, Fulvestrant, Aromatase Inhibitors adverse effects, Receptors, Estrogen analysis, Receptor, ErbB-2 genetics, Receptor, ErbB-2 analysis, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Mutation, Disease-Free Survival, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Neutropenia chemically induced, Lymphopenia chemically induced
Abstract

Background: In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1 mut ), while assessing the global safety of combination fulvestrant and palbociclib., Methods: We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1 mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1 mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1 mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete., Findings: From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1 mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related., Interpretation: PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1 mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials., Funding: Pfizer., Competing Interests: Declaration of interests F-CB reports, outside the submitted work, grants or contracts from Novartis, Lilly, Amgen, Sanofi, Radius, Seagen, AstraZeneca, General Electric, Menarini/Stemline, Menarini Silicon Biosystems, Merck, Pfizer, Prolynx, Rain Therapeutics, and Roche; consulting fees from AstraZeneca, Exact Sciences, General Electric, GlaxoSmithKline, Lilly, Menarini/Stemline, Novartis, Pfizer, Rain Therapeutics, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Lilly, Menarini/Stemline, Pfizer, Rain Therapeutics, and Sanofi; support for attending meetings or travel from AstraZeneca, Pfizer, Novartis, and Roche; and applied for an international patent (application number PCT/EP2019/056445), filed on March 14, 2019, named: method for identifying one or more mutations in a hotspot mutation sequence. A-CH-B reports, outside the submitted work, consulting fees from AstraZeneca and Merck Sharpe & Dohme; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, AstraZeneca, Daiichi, GSK, Seagen, and Gilead; support for attending meetings or travel from Novartis, Pfizer, and Daiichi; and participation on a data safety monitoring board or advisory board for MSD, AstraZeneca, Daiichi, Pfizer, Novartis, GSK, Seagen, Gilead, and Eisai. TB reports, outside the submitted work, grants or contracts from Roche, AstraZeneca, Pfizer, and SeaGen; and consulting fees from AstraZeneca, Daiichi, Lilly, SeaGen, Roche, Novartis, and Pfizer. J-YP reports, outside the submitted work, grants or contracts from Servier and Menarini; consulting fees from Pfizer, Daiichi Sankyo, AstraZeneca, and MSD; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Daiichi Sankyo, Gilead, MSD, Seagen, Novartis, Lilly, Pierre Fabre, and Amgen; support for attending meetings or travel from Roche and AstraZeneca; and participation on a data safety monitoring board or advisory board for Sanofi and Novartis. TdlMR reports, outside the submitted work, grants or contracts from Novartis, Pfizer, AstraZeneca, MSD, Roche, Pfizer, and Seagen; consulting fees from AstraZeneca, Clovis Oncology, Eisai, MSD, Novartis, Pfizer, Roche, Sanofi, Tesaro, GSK, and Seagen; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK. RS reports, outside the submitted work, grants or contracts from AstraZeneca; consulting fees from GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, GSK, Clovis, and AstraZeneca; and support for attending meetings or travel from Pfizer, Roche, GSK, and Bristol Myers Squibb. J-SF reports, outside the submitted work, consulting fees from Pfizer, Lilly, Novartis, AstraZeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, and Seagen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Lilly, Novartis, AstraZeneca, Gilead, Daiichi Sankyo, and Seagen; and support for attending meetings or travel from Pfizer, Lilly, Novartis, AstraZeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, and Seagen. SL reports, outside the submitted work, grants or contracts from Novartis, Eisai, and BMS; consulting fees from Pfizer, Novartis, Lilly, AstraZeneca, Sanofi, Astellas, Janssen, Ipsen, Roche, BMS, Daiichi, Seagen, and Pierre Fabre; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer, Novartis, Lilly, AstraZeneca, Sanofi, Astellas, Janssen, Ipsen, Roche, BMS, Daiichi, Seagen, and Pierre Fabre; payment for expert testimony from Pfizer, Novartis, Lilly, AstraZeneca, Sanofi, Astellas, Janssen, Ipsen, Roche, BMS, Daiichi, and Seagen; support for attending meetings or travel from Pfizer, Novartis, AstraZeneca, Janssen, BMS, Daiichi, and Seagen; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from BMS. CL reports, outside the submitted work, consulting fees from MSD, Daiichi, Roche, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Lilly; support for attending meetings or travel from Roche, Pfizer, Sandoz, Lilly, and AstraZeneca; and participation on a data safety monitoring board or advisory board for Roche, AstraZeneca, and Lilly. AL reports, outside the submitted work, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, and Clovis; participation on a data safety monitoring board or advisory board for AstraZeneca, MSD, and Clovis; and leadership or fiduciary role in other board for GINECO group. JG reports, outside the submitted work, support for attending meetings or travel from Lilly and Daiichi; and participation on a data safety monitoring board or advisory board for Daiichi and Pfizer. HV reports, outside the submitted work, grants or contracts from Eisai, Novartis, AstraZeneca, Daiichi, and Pfizer; and support for attending meetings or travel from Eisai, GSK, MSD, and Novartis. CG-T reports, outside the submitted work, grants or contracts from Pfizer; consulting fees from Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astrazeneca, Pfizer and Novartis; and support for attending meetings or travel from MSD, Mylan, and Pfizer. BP reports, outside the submitted work, consulting fees from AstraZeneca, Myriad, Pierre Fabre, and Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Daiichi Sankyo, Novartis, and Puma; support for attending meetings or travel from AstraZeneca, Pierre Fabre, and MSD; and participation on a data safety monitoring board or advisory board for Novartis, AstraZeneca, and Daiichi Sankyo. FA reports, outside the submitted work, reports grants or contracts from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, and Lilly; and consulting fees from Gilead, Guardant Health, MedImmune, and Relay Therapeutics. LA reports, outside the submitted work, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, MSD, AstraZeneca, and BMS; and support for attending meetings or travel from Roche. JL reports a Pfizer grant to his institution for carrying out this study. SD reports, outside the submitted work, grants or contracts from AstraZeneca, Pfizer, Novartis, Roche Genentech, Lilly, Puma, Myriad, Orion, Amgen, Sanofi, MSD, BMS, Seagen, and Taiho; consulting fees from Isis/Servier, Cellectis, Pierre Fabre, and General Electric; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Seagen, AstraZeneca, Pfizer, Exact Sciences, Daiichi, and Lilly; support for attending meetings or travel from Pfizer, AstraZeneca, and Roche Genentech; and participation on a data safety monitoring board or advisory board for AstraZeneca, Sanofi, Orion, and Rappta. All other authors declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

14. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.

Author

Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, Floquet A, Vegas H, Bourgeois H, Bengrine Lefevre L, You B, Pommeret F, Lortholary A, Spaeth D, Hardy-Bessard AC, Abdeddaim C, Kaminsky-Forrett MC, Tod M, Kurtz JE, Del Piano F, Meunier J, Raban N, Alexandre J, Mouret-Reynier MA, Ray-Coquard I, Provansal Gross M, and Brachet PE

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Bevacizumab, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial etiology, Female, Humans, Indazoles, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local etiology, Pyrimidines, Sulfonamides, Ovarian Neoplasms etiology, Paclitaxel
Abstract

Background: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab., Methods: In the randomized phase II TAPAZ trial, patients with rOC during the first year of bevacizumab maintenance therapy were assigned 2:1 to either weekly paclitaxel 65 mg/m 2 plus pazopanib 600-800 mg daily or standard weekly paclitaxel 80 mg/m 2 . The primary endpoint was 4-month progression-free survival (PFS) rate., Results: Overall, 116 patients were randomized and treated: 79 with combination therapy and 37 with single-agent paclitaxel. Median follow-up was 13.1 months. There was no difference between treatment arms in 4-month PFS rate (61% [95% CI, 51-73%] with the combination versus 68% [95% CI, 54-85%] with paclitaxel alone), median PFS (4.9 [95% CI, 4.1-6.1] versus 5.8 [95% CI, 4.8-7.4] months, respectively) or median overall survival (13.6 versus 12.9 months, respectively). The combination was associated with more grade 3/4 toxicities (87% versus 70%, respectively) and toxicity-related paclitaxel discontinuations (22% versus 11%). Pazopanib was discontinued for toxicity in 44% of patients, most commonly for gastrointestinal and vascular events. There were two treatment-related deaths, both in the combination arm (pulmonary embolism and gastrointestinal perforation). At month 4, patient-reported outcomes deteriorated from baseline in the combination arm, particularly for abdominal/gastrointestinal symptoms, which showed a clinically important difference versus paclitaxel alone., Conclusions: In rOC progressing during maintenance bevacizumab, adding pazopanib to paclitaxel did not improve efficacy, increased toxicity, and compromised chemotherapy delivery., Clinicaltrials: govregistration:NCT02383251., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

15. Unexpected severe hepatic and skin toxicities during high dose methotrexate course for osteosarcoma.

Author

Salaün H, Le Nail LR, Simon C, Narciso B, De Pinieux G, Vegas H, and Vinceneux A

Subjects
Adolescent, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Female, Humans, Liver-Specific Organic Anion Transporter 1, Methotrexate adverse effects, Bone Neoplasms drug therapy, Osteosarcoma drug therapy, Renal Insufficiency chemically induced, Stevens-Johnson Syndrome etiology
Abstract

Introduction: high dose methotrexate (HD-MTX) regimen is used in osteosarcoma, leukemia and lymphoma treatment. Osteosarcoma is mostly diagnosed in children and adolescents. Most frequent methotrexate toxicities are mucositis, myelosuppression, renal failure, hepatitis and necrotizing encephalopathy. Toxicities increase with renal impairment, denutrition, in older patients, with some pharmacogenetics factors or with drug interactions., Case Report: We report a 16th years old woman diagnosed with osteosarcoma and experienced an unexpected severe hepatic and skin toxicities as toxic epidermal necrolys, Steven Johnson syndrome., Management and Outcome: This toxicity occurred despite acid folinic rescue performed as good practice recommendation. Fourteen hours after methotrexate administration, renal failure was observed and after 72 h an erythematous rash and epidermal detachment with toxic epidermal necrolys. Seven days after methotrexate administration, hepatic failure began until grade IV cytolysis. High dose of folinic acid were administered during all severe toxicities. Methotrexate were not longer administered to this young patient and chemotherapy with ifosfamide (IFO), doxorubicine and cisplatin were performed in this patient and complete histologic response were observed in the surgical bone resection., Discussion: No classical toxicities risk factors were identified in this patient but a homozygote mutation of MTHFR gene and homozygote SLCO1B1 gene mutation were found. MTHFR and SLCO1B1 are both implicated in methotrexate metabolism.

Published
2022
Full Text
View/download PDF

16. Cross-Cultural Adaptation and Psychometric Validation of the French Version of the FAMCARE-Patient (FFP-16) Questionnaire for Outpatients With Advanced-Stage Cancer.

Author

Chaumier F, Flament T, Lecomte T, Vegas H, Stacoffe M, Pichon E, Narciso B, Caulet M, Barbe C, Jaillais A, Carmier D, By MA, Bourdon M, and Hardouin JB

Subjects
Adult, Cross-Sectional Studies, Humans, Outpatients, Psychometrics, Quality of Life, Reproducibility of Results, Surveys and Questionnaires, Cross-Cultural Comparison, Neoplasms therapy
Abstract

Context: Satisfaction is known to be correlated with the quality of care; it indicates the adequacy of the caregivers' responses in meeting the needs and expectations of patients. The FAMCARE-Patient questionnaire has been used to quantify satisfaction level in outpatients with advanced-stage cancers., Objectives: To translate and cross-culturally adapt the FAMCARE-Patient questionnaire for French patients and to evaluate the psychometric properties of this version., Methods: The original questionnaire was translated into French and adapted to French cultural context by an expert committee. The French FAMCARE-Patient Version 16 (FFP-16) was then pilot tested among 51 patients. Subsequently, psychometric properties were evaluated in a cross-sectional study by administrating the new tool to 176 adult outpatients with advanced-stage cancer who underwent oncological care at our university hospital., Results: We performed a confirmatory factor analysis and assessed the reliability and validity of the questionnaire. The one-factor structure was confirmed, and it had an acceptable fit with a comparative fit index and root mean square error of approximation of 0.93 and 0.07, respectively. Internal reliability was high as shown by Cronbach's alpha (α = 0.95). Reproducibility was very good (intraclass correlation coefficient 0.91). The FFP-16 score was independent of the Eastern Cooperative Oncology Group and the overall Edmonton Symptom Assessment Scale distress scores. It was significantly but weakly correlated with anxiety, well-being, and overall quality of life (Spearman's correlation coefficient = -0.18, -0.20, and 0.30, respectively; P < 0.05)., Conclusion: We found the FFP-16 questionnaire to be a reliable and valid instrument for the assessment of satisfaction in French outpatients with advanced-stage cancer., (Copyright © 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

17. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection].

Author

Guillaume C, Vegas H, Pastuszka A, Le Brun C, and Lanotte P

Subjects
Adult, Artifacts, Breast Neoplasms cerebrospinal fluid, Breast Neoplasms pathology, Cerebrospinal Fluid cytology, Cytarabine cerebrospinal fluid, Female, Humans, Injections, Spinal, Leukocytes cytology, Meningeal Neoplasms cerebrospinal fluid, Meningeal Neoplasms secondary, Antimetabolites, Antineoplastic administration & dosage, Breast Neoplasms drug therapy, Cerebrospinal Fluid chemistry, Cytarabine administration & dosage, Liposomes cerebrospinal fluid, Meningeal Neoplasms drug therapy
Abstract

The patient is a 36 year old female who presented breast cancer with leptomeningeal involvement. A systematic lumbar puncture was performed and sent to the laboratory for CSF analysis. CSF examination using wet mount preparation showed a large number of round spherules. After discussion with the ordering physician, we learnt that the patient had received intrathecal liposomal cytarabine injection 19 days earlier. Cytarabine liposomes are spherules with a granular interior and range in size from 10-30 μm. It can be confused with leukocytes and lead to spurious elevation of CSF leukocytes count. Care needs to be taken in interpreting CSF results in patients who have received intrathecal liposomal cytarabine.

Published
2018
Full Text
View/download PDF

18. Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature.

Author

Ogielska M, Lanotte P, Le Brun C, Valentin AS, Garot D, Tellier AC, Halimi JM, Colombat P, Guilleminault L, Lioger B, Vegas H, De Toffol B, Constans T, and Bernard L

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Clostridioides difficile immunology, Clostridium Infections mortality, Community-Acquired Infections mortality, Cross Infection mortality, Diarrhea epidemiology, Diarrhea virology, Female, France epidemiology, Hospitals, University, Humans, Long-Term Care, Male, Middle Aged, Prospective Studies, Retrospective Studies, Risk Factors, Young Adult, Clostridioides difficile isolation & purification, Clostridium Infections embryology, Community-Acquired Infections epidemiology, Cross Infection epidemiology
Abstract

Background: Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhoea. People in the general community are not usually considered to be at risk of CDI. CDI is associated with a high risk of morbidity and mortality. The risk of severity is defined by the Clostridium Severity Index (CSI)., Methods: The cases of 136 adult patients with CDI treated at the University Hospital of Tours, France between 2008 and 2012 are described. This was a retrospective study., Results: Among the 136 patients included, 62 were men and 74 were women. Their median age was 64.4 years (range 18-97 years). Twenty-six of the 136 (19%) cases were community-acquired (CA) and 110 (81%) were healthcare-acquired (HCA). The major risk factors for both groups were long-term treatment with proton pump inhibitors (54% of CA, 53% of HCA patients) and antibiotic treatment within the 2.5 months preceding the CDI (50% of CA, 91% of HCA). The CSI was higher in the CA-CDI group (1.56) than in the HCA-CDI group (1.39). Intensive care was required for 8% of CA-CDI and 16.5% of HCA-CDI patients., Conclusions: CDI can cause community-acquired diarrhoea, and CA-CDI may be more severe than HCA-CDI. Prospective studies of CDI involving people from the general community without risk factors are required to confirm this observation., (Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2015
Full Text
View/download PDF

19. [Disseminated and circulating tumor cells in gastrointestinal oncology].

Author

Vegas H, André T, Bidard FC, Ferrand FR, Huguet F, Mariani P, and Pierga JY

Subjects
Bone Marrow Neoplasms therapy, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular therapy, Colorectal Neoplasms blood, Colorectal Neoplasms pathology, Colorectal Neoplasms therapy, Digestive System Neoplasms blood, Digestive System Neoplasms therapy, Esophageal Neoplasms blood, Esophageal Neoplasms pathology, Esophageal Neoplasms therapy, Humans, Liver Neoplasms blood, Liver Neoplasms pathology, Liver Neoplasms therapy, Pancreatic Neoplasms blood, Pancreatic Neoplasms pathology, Pancreatic Neoplasms therapy, Stomach Neoplasms blood, Stomach Neoplasms pathology, Stomach Neoplasms therapy, Biomarkers, Tumor blood, Bone Marrow Neoplasms pathology, Digestive System Neoplasms pathology, Neoplastic Cells, Circulating pathology
Abstract

Circulating (CTC) and disseminated tumor cells (DTC) represent two different steps of the metastatic process. As with other types of cancer, the recent development of techniques for the detection of CTC and DTC respectively in the blood and bone marrow of patients generated many results in digestive cancers. However, the interpretation of these results and of the prognostic value of CTC/DTC is often limited by the small cohort size and the heterogeneity of detection methods. The aim of this article is to review the different results and their clinical impact, and discuss the possible use of CTC and DTC as new biomarkers. First of all, it is important to take into account the variability of epithelial markers used for the initial stage of immunoselection of CTC/DTC as well as that of molecular or cytological markers used for the second stage of detection. In esophageal, gastric, pancreatic and hepatocellular carcinomas, and in the ileal and pancreatic neuroendocrine tumors, some studies showed a correlation between the detection of CTC and/or DTC and a clinical pejorative course, whether these tumors were at localized or metastatic stages. On colorectal cancer in the adjuvant setting, a recent meta-analysis showed an association between the detection of CTC in peripheral blood and disease-free survival or overall survival. These results are consistent with those of a study that identified detection of CTC as a prognostic factor for relapse in stage II. This last study concluded that it was necessary to achieve long-term evaluation of CTC as a biomarker to guide the decisions of chemotherapy for stage II. In metastatic colorectal cancer, the FDA approved in 2007 the use of pretherapeutic levels of CTC and its variations per-treatment, determined by CellSearch(®) technology, as a tool in treatments management. However, the modalities of this monitoring have to be specified and clinical benefit or the cost-effectiveness of a treatment based on this new biomarker has to be evaluated. Finally, the qualitative and quantitative monitoring of CTC could be a non-invasive tool to monitor changes in tumor biology throughout the disease, and thereby improve the understanding of the processes of dissemination and therapeutic resistance.

Published
2012
Full Text
View/download PDF

20. [Cryptococcosis in Venezuela. Comments on a clinical case with unusual location].

Author

Campins H, Galavis D, and Vegas H

Subjects
Adolescent, Adult, Cryptococcosis epidemiology, Cryptococcosis pathology, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Retroperitoneal Neoplasms diagnosis, Venezuela, Cryptococcosis diagnosis
Abstract

A tumor like case of Cryptococcosis with a rare location in the abdomen of a young healthy woman is commented. It gave the opportunity to refer to the pathogeny of the disease, making in that way a brief review of the cases known in Venezuela and some not still published from which we got information. That review showed that generally doctors found more frequently organic lesions within the fields they are specially working for. It is obvious that mycosis must be considered in the diagnosis of nearly every patient in many countries and that laboratories must get appropriate equipment and personnel to help in that diagnosis.

Published
1975
Full Text
View/download PDF

21. [Use of esophageal cytology. Comparative study on the value of various methods (III)].

Author

Poleo JR, Vegas HJ, and Acevedo F

Subjects
Evaluation Studies as Topic, Humans, Biopsy methods, Esophageal Neoplasms diagnosis
Abstract

Several esophageal cytologic tecniques (sponge biopsy, sponge smear, and espohageal washings) were assessed and compared with endoscopy and biopsy of esophageal tumors. Esophageal cytology rendered better results than esophagoscopy or biopsy, with a 97% positivity in cases of esophageal carcinoma, when using sponge biopsy and sponge smear techniques, and of 91.4% for esophageal and gastric carcinoma of the fundus invading gastroesophageal junction, when considered together. The combination of sponge techniques was better for diagnosisng esophageal carcinoma than the application of esophageal washings, a more difficult, time consuming, and sometimes unfeasible method. However, the utilization of three mehtods enhanced the overall diagnostic possibilities in all cases of esophageal tumors when considered together.

Published
1975

22. The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima-media extracts.

Author

Camejo G, Lopez A, Vegas H, and Paoli H

Subjects
Animals, Aorta pathology, Blood Protein Electrophoresis, Immunoelectrophoresis, Rabbits, Aorta analysis, Lipoproteins blood, Proteins analysis
Abstract

Summary: A factor of protein nature that forms specific complexes with low density lipoproteins (LDL) has been detected in extracts of aortic intima-media from men and rabbits. Although the formation of complexes is maximal at low ionic strength, it is still observed under physiological conditions. Gel electrophoresis of the complex formed between the extracts and LDL proteins indicates that the insoluble material is an aggregate of the lipoproteins with some of the proteins present in the extracts. Pretreatment of the intima-media extract with proteases greatly diminishes its complexing ability. The interaction was also observed between the extracts and sera. The sera from patients with myocardial infarct formed more insoluble complexes than the sera from a control group. The lipoprotein complexing agent was found in intima-media of aorta and coronary arteries but not in that of veins, pulmonary arteries or in the adventitia of arteries or veins.

Published
1975
Full Text
View/download PDF

23. [Diagnosis of esophageal neoplasms by sponge biopsy (I)].

Author

Poleo JR and Vegas HJ

Subjects
Cytodiagnosis methods, Evaluation Studies as Topic, Gelatin, Humans, Biopsy methods, Esophageal Neoplasms diagnosis
Abstract

Fifty-one (51) patients with carcinoma of the esophagus, 27 with cancer of the gastric fundus invading gastroesophageal junction, and 28 controls with non-tumoral esophageal problems were studied by the sponge biopsy technique, an effective procedure for cytologyc diagnosis of esophageal tumors. Various advantages of this technique over esophageal washings are described and results with the sponge biopsy technique are favorably compared with them.

Published
1975

Catalog

Books, media, physical & digital resources
See catalog results